Spots Global Cancer Trial Database for panobinostat
Every month we try and update this database with for panobinostat cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01460940 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | panobinostat lenalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy | NCT01056601 | Pancreatic Canc... | Bortezomib Panobinostat | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery | NCT00873002 | Liver Cancer | panobinostat sorafenib tosyl... | 18 Years - | Case Comprehensive Cancer Center | |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | NCT02722941 | Multiple Myelom... | Panobinostat | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | NCT01802879 | Hematologic Neo... | Panobinostat | - | Novartis | |
| Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | NCT01582009 | Clear Cell Rena... Recurrent Renal... Stage III Renal... Stage IV Renal ... | panobinostat everolimus laboratory biom... pharmacological... liquid chromato... mass spectromet... enzyme-linked i... immunohistochem... | 18 Years - | Roswell Park Cancer Institute | |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | NCT01242774 | Acute Myeloid L... | Panobinostat | 18 Years - 65 Years | Novartis | |
| LBH Phase II in Small Cell Lung Cancer (SCLC) | NCT01222936 | Small Cell Lung... | LBH581 | 18 Years - 75 Years | Southern Europe New Drug Organization | |
| An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | NCT02568943 | Multiple Myelom... | Panobinostat | 18 Years - | Novartis | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | NCT02145715 | Multiple Myelom... | Velcade Thalidomide Dexamethasone Panobinostat | 18 Years - | University of Leeds | |
| LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors | NCT01159418 | Advanced Solid ... | Panobinostat (L... | 18 Years - 75 Years | Southern Europe New Drug Organization | |
| Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | NCT00490776 | Cutaneous T-Cel... | Panobinostat | 18 Years - | Novartis | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | NCT01136499 | Soft Tissue Sar... | LBH589 (Panobin... | 18 Years - | Centre Leon Berard | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | NCT01005797 | Renal Cancer Non Small Cell ... Soft Tissue Sar... | Panobinostat (L... | 18 Years - | Medical University of South Carolina | |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | NCT01802879 | Hematologic Neo... | Panobinostat | - | Novartis | |
| Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT01282476 | Diffuse Large B... | Panobinostat wi... | 18 Years - | Massachusetts General Hospital | |
| Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | NCT00743288 | Multiple Myelom... | Melphalan Panobinostat | 18 Years - | Oncotherapeutics | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Panobinostat/Velcade in Multiple Myeloma | NCT00891033 | Multiple Myelom... | Bortezomib (Vel... Panobinostat | 18 Years - | University of Arkansas | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | NCT01136499 | Soft Tissue Sar... | LBH589 (Panobin... | 18 Years - | Centre Leon Berard | |
| Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | NCT02032810 | Melanoma Skin Cancer | Panobinostat Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Diffuse Large B... | LBH589 Rituximab | 18 Years - | Jewish General Hospital | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) | NCT00840346 | Acute Myeloblas... | panobinostat | 65 Years - | PETHEMA Foundation | |
| Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors | NCT00878904 | Unspecified Adu... | epirubicin hydr... panobinostat gene expression... protein express... western blottin... immunologic tec... laboratory biom... pharmacological... | 18 Years - 120 Years | University of California, San Francisco | |
| A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | NCT01965353 | Multiple Myelom... | Panobinostat Dexamethasone Lenalidomide Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS | NCT04326764 | Acute Myeloid L... Myelodysplastic... | Panobinostat | 18 Years - 70 Years | Goethe University | |
| Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors | NCT01336842 | Solid Tumors Non-Small Cell ... | Panobinostat, C... | 18 Years - | University of California, Davis | |
| A Panobinostat Presurgery | NCT01115036 | Recurrent Gliob... | panobinostat | 18 Years - | Duke University | |
| Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | NCT02145715 | Multiple Myelom... | Velcade Thalidomide Dexamethasone Panobinostat | 18 Years - | University of Leeds | |
| Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma | NCT02204553 | Multiple Myelom... | Panobinostat | 18 Years - | Novartis | |
| Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | NCT00878436 | Prostate Cancer Prostatic Neopl... | Panobinostat Bicalutamide | 18 Years - | NYU Langone Health | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | NCT02802163 | Multiple Myelom... | Panobinostat Carfilzomib Lenalidomide Dexamethasone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | NCT01005797 | Renal Cancer Non Small Cell ... Soft Tissue Sar... | Panobinostat (L... | 18 Years - | Medical University of South Carolina | |
| Panobinostat/Velcade in Multiple Myeloma | NCT00891033 | Multiple Myelom... | Bortezomib (Vel... Panobinostat | 18 Years - | University of Arkansas | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT00723203 | Leukemia | panobinostat gene expression... reverse transcr... laboratory biom... | 18 Years - | City of Hope Medical Center | |
| Panobinostat Biological Correlates Study | NCT01658241 | Nodal Lymphoma Lymphoma With C... Lymphoma in Leu... Marrow Involvem... Multiple Myelom... | panobinostat | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | NCT02057640 | Multiple Myelom... Kahler Disease Plasma-Cell Mye... Myelomatosis | Panobinostat Dexamethasone MLN9708 | 18 Years - | Case Comprehensive Cancer Center | |
| Trial of LBH589 in Metastatic Thyroid Cancer | NCT01013597 | Thyroid Carcino... | LBH589 | 18 Years - | University of Wisconsin, Madison | |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | NCT00936611 | Waldenstrom's M... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | NCT02057640 | Multiple Myelom... Kahler Disease Plasma-Cell Mye... Myelomatosis | Panobinostat Dexamethasone MLN9708 | 18 Years - | Case Comprehensive Cancer Center | |
| Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma | NCT01023308 | Multiple Myelom... | Panobinostat Bortezomib Dexamethasone Placebo | 18 Years - | Novartis | |
| Panobinostat Biological Correlates Study | NCT01658241 | Nodal Lymphoma Lymphoma With C... Lymphoma in Leu... Marrow Involvem... Multiple Myelom... | panobinostat | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) | NCT00691938 | Leukemia, Myelo... Myelodysplastic... | LBH589 Decitabine | 60 Years - | Washington University School of Medicine | |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | NCT01613976 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat | 20 Years - | Novartis | |
| LBH Phase II in Small Cell Lung Cancer (SCLC) | NCT01222936 | Small Cell Lung... | LBH581 | 18 Years - 75 Years | Southern Europe New Drug Organization | |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) | NCT01451268 | Myelodysplastic... Acute Myeloid L... | Panobinostat Panobinostat | 18 Years - | Johann Wolfgang Goethe University Hospital | |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat | NCT04150289 | Multiple Myelom... | Farydak | 18 Years - | pharmaand GmbH | |
| Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors | NCT01324635 | Recurrent Gliom... High-grade Meni... Brain Metastasi... | Panobinostat Stereotactic bo... Quality-of-life... Stereotactic ra... | 18 Years - | Thomas Jefferson University | |
| Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | NCT01463046 | Acute Myeloid L... Advanced Myelod... | Panobinostat Cytarabine Daunorubicin | 18 Years - | University of California, San Francisco | |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG | NCT04341311 | Diffuse Intrins... Pediatric Brain... Pediatric Brain... Pediatric Cance... Pediatric Brain... Diffuse Glioma | Marizomib Panobinostat | - 21 Years | Dana-Farber Cancer Institute | |
| Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer | NCT00667862 | Prostate Cancer | Panobinostat | 18 Years - | Novartis | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat | NCT04150289 | Multiple Myelom... | Farydak | 18 Years - | pharmaand GmbH | |
| Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma | NCT01083602 | Relapsed and Bo... Refractory Mult... Multiple Myelom... | panobinostat bortezomib dexamethasone | 18 Years - | Novartis | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center | |
| Panobinostat (LBH589) in Patients With Metastatic Melanoma | NCT01065467 | Melanoma Malignant Melan... | LBH589 | 18 Years - | Dana-Farber Cancer Institute | |
| Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors | NCT01324635 | Recurrent Gliom... High-grade Meni... Brain Metastasi... | Panobinostat Stereotactic bo... Quality-of-life... Stereotactic ra... | 18 Years - | Thomas Jefferson University | |
| LBH589 in Refractory Myelodysplastic Syndromes (MDS) | NCT00594230 | Myelodysplastic... | Panobinostat | 18 Years - | SCRI Development Innovations, LLC | |
| Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma | NCT01301807 | Non-Secretory P... Plasmacytosis Recurrent Plasm... Refractory Plas... | Carfilzomib Panobinostat | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | NCT00670553 | Prostate Cancer Head & Neck Can... Esophageal Canc... | panobinostat | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
